سعر سموفكابيفن بريفرال 1300كيلو كالوري مستحلب للتنقيط الوريدي 1904 مل bag: glucose 2024

SmofKabiven Peripheral 1904 ml three-chamber bag (Fresenius Kabi) with glucose 13%, amino acids with electrolytes and a four-oil lipid emulsion, for peripheral or central intravenous parenteral nutrition; about 1300 kcal per bag.

• Parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.Population: Adults and children aged 2 years and aboveLäkemedelsverket (Swedish Medical Products Agency)

• Common: slight rise in body temperature, thrombophlebitis. Uncommon: lack of appetite, nausea, vomiting, raised liver enzymes, chills, dizziness, headache. Rare: tachycardia, dyspnoea, hypotension, hypertension, hypersensitivity reactions. Fat overload syndrome possible.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)

• Hypersensitivity to fish, egg, soya or peanut protein or to any active substance or excipient.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)
• Severe hyperlipidaemia; severe liver insufficiency; severe blood coagulation disorders; congenital errors of amino acid metabolism; severe renal insufficiency without access to haemofiltration or dialysis.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)
• Acute shock; uncontrolled hyperglycaemia; pathologically elevated serum electrolytes; acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency; haemophagocytotic syndrome; unstable conditions (e.g. severe post-traumatic states, uncompensated diabetes, acute myocardial infarction, stroke, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration, hyperosmolar coma).International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)

• Monitor lipid elimination (serum triglycerides should not exceed 4 mmol/l during infusion); caution in impaired lipid metabolism (renal failure, diabetes, pancreatitis, impaired liver function, hypothyroidism, sepsis).International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)
• Contains soya-bean oil, fish oil and egg phospholipids (rare allergic reactions; soya-peanut cross-reactions); stop immediately at any sign of anaphylaxis.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)
• Correct fluid/electrolyte disturbances before starting; strict asepsis; refeeding risk in malnourished patients (start slowly); thrombophlebitis with peripheral veins; not with blood in the same set; lipids may interfere with some laboratory tests.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)

• InsulinSome medicines such as insulin may interfere with the body's lipase system; limited clinical importance.Läkemedelsverket (Swedish Medical Products Agency)
• HeparinClinical doses cause transient release of lipoprotein lipase: increased lipolysis followed by transiently decreased triglyceride clearance.Läkemedelsverket (Swedish Medical Products Agency)
• Coumarin derivativesVitamin K1 content of soya-bean oil is too low to be expected to significantly influence coagulation.Läkemedelsverket (Swedish Medical Products Agency)

• No data in pregnant or breast-feeding women and no reproductive toxicity studies; parenteral nutrition may become necessary; give only after careful consideration.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)
• No data in breast-feeding women; use only after careful consideration.International label, same formulation · Läkemedelsverket (Swedish Medical Products Agency)